The Liver in Heart Failure: From Biomarkers to Clinical Risk
International Journal of Molecular Sciences · 27.10.2023 · 24 (21) · 15665
DOI: 10.3390/ijms242115665 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.10.2023. Verfasst von Nadia Aspromonte und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy. Hauptthemen laut MEDLINE: Liver Diseases, Heart Failure, Elasticity Imaging Techniques. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) is a clinical syndrome due to heart dysfunction, but in which other organs are also involved, resulting in a complex multisystemic disease, burdened with high mortality and morbidity. This article focuses on the mutual relationship between the heart and liver in HF patients. Any cause of right heart failure can cause hepatic congestion, with important prognostic significance. We have analyzed the pathophysiology underlying this double interaction. Moreover, we have explored several biomarkers and non-invasive tests (i.e., liver stiffness measurement, LSM) potentially able to provide important support in the management of this complex disease. Cardiac biomarkers have been studied extensively in cardiology as a non-invasive diagnostic and monitoring tool for HF. However, their usefulness in assessing liver congestion in HF patients is still being researched. On the other hand, several prognostic scores based on liver biomarkers in patients with HF have been proposed in recent years, recognizing the important burden that liver involvement has in HF. We also discuss the usefulness of a liver stiffness measurement (LSM), which has been recently proposed as a reliable and non-invasive method for assessing liver congestion in HF patients, with therapeutic and prognostic intentions. Lastly, the relationship between LSM and biomarkers of liver congestion is not clearly defined; more research is necessary to establish the clinical value of biomarkers in assessing liver congestion in HF patients and their relationship with LSM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy.
- Department of Cardiovascular and Thoracic Sciences, A. Gemelli University Policlinic Foundation IRCCS, 00168 Rome, Italy.
- Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, 00168 Rome, Italy.
- Department of Medical and Surgical Sciences, A. Gemelli University Policlinic Foundation IRCCS, 00168 Rome, Italy.
ORCID-Profile: Isabella Fumarulo, Antonio Liguori, Luca Miele
Zitieren
APA
Aspromonte, N., Fumarulo, I., Petrucci, L., Biferali, B., Liguori, A., Gasbarrini, A., Massetti, M., & Miele, L. (2023). The Liver in Heart Failure: From Biomarkers to Clinical Risk. International Journal of Molecular Sciences, 24(21), 15665. https://doi.org/10.3390/ijms242115665
Vancouver
Aspromonte N, Fumarulo I, Petrucci L, Biferali B, Liguori A, Gasbarrini A, et al. The Liver in Heart Failure: From Biomarkers to Clinical Risk. International Journal of Molecular Sciences. 2023;24(21):15665. doi:10.3390/ijms242115665
BibTeX
@article{Aspromonte2023,
author = {Aspromonte, Nadia and Fumarulo, Isabella and Petrucci, Lucrezia and Biferali, Bianca and Liguori, Antonio and Gasbarrini, Antonio and Massetti, Massimo and Miele, Luca},
title = {The Liver in Heart Failure: From Biomarkers to Clinical Risk},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {21},
pages = {15665},
doi = {10.3390/ijms242115665}
}
EUVIMED